Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SLAMF1/CD150 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLAMF1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View SLAMF1 Products |
| Gene Delivery | SLAMF1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and surface expression validation. |
View SLAMF1 Products |
| Benchmark Ab | Anti-SLAMF1 Recombinant Antibody Recombinant positive control for binding and functional assays. |
View SLAMF1 Products |
| Validator | SLAMF1 siRNA Set For knockdown verification in target-expressing immune cells. |
View SLAMF1 Products |
| Related Target A | SLAMF7 Critical co-target in hematological malignancies (e.g., Multiple Myeloma) and immunotherapy. |
View SLAMF7 Products |
| Related Target B | CD48 Key SLAM family receptor involved in immune cell activation and costimulatory signaling. |
View CD48 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homophilic interaction interference (SLAMF1-SLAMF1 self-binding) | HEK293 expressed recombinant SLAMF1 ECD-Fc with native glycosylation to mimic natural homophilic interface. |
| Soluble vs. membrane-bound target selectivity | Sequence-verified truncation variants and Lentivirus-mediated stable cell lines to isolate membrane-bound binding. |
| Lack of Controls | Sequence-verified recombinant benchmark antibodies included for assay standardization. |
| False Positives | Validated siRNA sets included for target-specific knockdown controls in flow cytometry. |
Live SLAMF1/CD150 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLAMF1/CD150 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and CAR-T therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting homophilic interaction blockade and selective targeting in hematological malignancies like cutaneous T-cell lymphoma (CTCL) and Hodgkin lymphoma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Academic Institutes, Biotech Startups | T-cell Lymphoma, Multiple Myeloma | Internalization Assay (Need high-purity ECD-Fc and stable cell lines) |
| CAR-T / Cell Therapy | Clinical Stage Biotechs | Hematological Malignancies | Target Density & Specificity Validation (Need Lentivirus for target cell line construction) |
| Monoclonal Antibody (mAb) | Oncology-focused Biopharma | Autoimmune diseases, Lymphoma | Homophilic Blockade Assay (Need native conformation recombinant proteins) |